Cargando…

Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents

After BNT162b2 messenger RNA vaccination, antibody levels to spike, receptor-binding domain, and virus neutralization were examined in 149 nursing home residents and 110 healthcare worker controls. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–naive nursing home residents’ median post...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canaday, David H, Carias, Lenore, Oyebanji, Oladayo A, Keresztesy, Debbie, Wilk, Dennis, Payne, Michael, Aung, Htin, St. Denis, Kerri, Lam, Evan C, Rowley, Christopher F, Berry, Sarah D, Cameron, Cheryl M, Cameron, Mark J, Wilson, Brigid, Balazs, Alejandro B, Gravenstein, Stefan, King, Christopher L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240817/ https://www.ncbi.nlm.nih.gov/pubmed/33993265 http://dx.doi.org/10.1093/cid/ciab447

Ejemplares similares

Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents
por: Canaday, David H., et al.
Publicado: (2021)

Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
por: Oyebanji, Oladayo A., et al.
Publicado: (2021)

Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination
por: Canaday, David H, et al.
Publicado: (2021)

Significantly elevated antibody levels and neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA booster vaccination
por: Canaday, David H., et al.
Publicado: (2021)

COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents
por: Canaday, David H., et al.
Publicado: (2022)

2373. "Longitudinal Investigation of Avidity Maturation following Multiple Doses of BNT162b2 mRNA Vaccine Including Bivalent Boosters among Nursing Home Residents and Healthcare Workers"
por: Oyebanji, Oladayo A, et al.
Publicado: (2023)

2396. In Nursing Home Residents, SARS-CoV-2 Boosters Reduced Sex Disparity in Vaccine Response Observed in Primary Series
por: Wilson, Brigid, et al.
Publicado: (2023)

SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine — Ohio and Rhode Island, September–November 2022
por: Canaday, David H., et al.
Publicado: (2023)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
por: Eduarda Andrade e Andrade, Maria, et al.
Publicado: (2022)

Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers
por: Freeman, Michael L, et al.
Publicado: (2023)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
por: Kahn, Benjamin, et al.
Publicado: (2021)

Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers
por: Greco, Marilena, et al.
Publicado: (2021)

Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination
por: Gravenstein, Stefan, et al.
Publicado: (2023)

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults
por: Oyebanji, Oladayo A., et al.
Publicado: (2023)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
por: Schramm, René, et al.
Publicado: (2021)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
por: Wu, Xiaotian, et al.
Publicado: (2021)

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination
por: Kim, A-Sol, et al.
Publicado: (2023)

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)
por: Li, Xue, et al.
Publicado: (2023)

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
por: Ammitzbøll, Christian, et al.
Publicado: (2021)

Specific antibody response of 14 patients with common variable immunodeficiency to 3 BNT162b2 messenger RNA coronavirus disease 2019 vaccinations
por: Abo-Helo, Nizar, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
por: Ando, Masaru, et al.
Publicado: (2022)

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
por: Bartsch, Yannic C., et al.
Publicado: (2022)

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
por: Ricardo, Jose W., et al.
Publicado: (2021)

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021)

Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years
por: Toepfner, Nicole, et al.
Publicado: (2022)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Extended interval BNT162b2 vaccination enhances peak antibody generation
por: Parry, Helen, et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody kinetics after BNT162B2 vaccination
por: Hettiarachchi, Ravin, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ibsmgha91q7qhgqn87gtc02k4